Ginkgo Bioworks Holdings Stock Today

DNA Stock  USD 1.09  0.01  0.93%   

Performance

0 of 100

 
Low
 
High
Very Weak

Odds Of Distress

Less than 42

 
100  
 
Zero
Below Average
Ginkgo Bioworks is trading at 1.09 as of the 18th of March 2024, a 0.93 percent up since the beginning of the trading day. The stock's open price was 1.08. Ginkgo Bioworks has about a 42 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. Equity ratings for Ginkgo Bioworks Holdings are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 29th of March 2022 and ending today, the 18th of March 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
19th of April 2021
Category
Healthcare
Classification
Health Care
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts. Ginkgo Bioworks operates under Biotechnology classification in the United States and is traded on New York Stock Exchange. The company has 1.65 B outstanding shares of which 255.72 M shares are currently shorted by investors with about 12.0 days to cover. More on Ginkgo Bioworks Holdings

Moving together with Ginkgo Stock

  0.63VALN Valneva SE ADR Earnings Call This WeekPairCorr

Moving against Ginkgo Stock

  0.68REGN Regeneron Pharmaceuticals Financial Report 2nd of May 2024 PairCorr
  0.6APGE Apogee TherapeuticsPairCorr
  0.57MRK Merck Company Sell-off TrendPairCorr
  0.56ALVO Alvotech Earnings Call This WeekPairCorr
  0.43JNJ Johnson Johnson Fiscal Quarter End 31st of March 2024 PairCorr

Ginkgo Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Ginkgo Bioworks' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Ginkgo Bioworks or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
CEOKenny Goh
Thematic IdeaBiotech (View all Themes)
Old Names[Doric Nimrod Air One Limited, Dalradian Resources Inc, DNA Oyj, More Return Public Company Limited]
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NYSE Composite, Biotech, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Analysts covering Ginkgo Bioworks report their recommendations after researching Ginkgo Bioworks' financial statements, talking to executives and customers, or listening in on Ginkgo Bioworks' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Ginkgo Bioworks Holdings. The Ginkgo consensus assessment is calculated by taking the average forecast from all of the analysts covering Ginkgo Bioworks.
Financial Strength
Based on the key indicators related to Ginkgo Bioworks' liquidity, profitability, solvency, and operating efficiency, Ginkgo Bioworks Holdings may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter. Financial strength of Ginkgo Bioworks Holdings is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.0960.151
Way Down
Slightly volatile
Gross Profit Margin0.690.5673
Fairly Up
Slightly volatile
Total Current Liabilities128.7 M163.9 M
Significantly Down
Slightly volatile
Non Current Liabilities Total422.2 M404.3 M
Sufficiently Up
Slightly volatile
Total Assets1.7 B1.7 B
Fairly Up
Slightly volatile
Total Current Assets1.1 BB
Moderately Up
Slightly volatile
Ginkgo Bioworks' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Ginkgo Bioworks' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Ginkgo Bioworks' financial leverage. It provides some insight into what part of Ginkgo Bioworks' total assets is financed by creditors.
By using current balance sheet information, investors can analyze the liability, assets, and equity on Ginkgo Bioworks' books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Ginkgo Bioworks deploys its capital and how much of that capital is borrowed.
Liquidity
Ginkgo Bioworks cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company has 241.77 M in debt with debt to equity (D/E) ratio of 0.03, which may show that the company is not taking advantage of profits from borrowing. Ginkgo Bioworks Holdings has a current ratio of 11.6, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Debt can assist Ginkgo Bioworks until it has trouble settling it off, either with new capital or with free cash flow. So, Ginkgo Bioworks' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Ginkgo Bioworks Holdings sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Ginkgo to invest in growth at high rates of return. When we think about Ginkgo Bioworks' use of debt, we should always consider it together with cash and equity.

Sale Purchase Of Stock

0.0
Ginkgo Bioworks Holdings (DNA) is traded on New York Stock Exchange in USA. It is located in 27 Drydock Avenue, Boston, MA, United States, 02210 and employs 1,218 people. Ginkgo Bioworks is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a total capitalization of 2.32 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Ginkgo Bioworks's market, we take the total number of its shares issued and multiply it by Ginkgo Bioworks's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Ginkgo Bioworks Holdings runs under Biotechnology sector within Health Care industry. The entity has 1.65 B outstanding shares of which 255.72 M shares are currently shorted by investors with about 12.0 days to cover. Ginkgo Bioworks Holdings has about 1.32 B in cash with (295.5 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.84.
Check Ginkgo Bioworks Probability Of Bankruptcy
Ownership Allocation
Ginkgo Bioworks secures a total of 1.65 Billion outstanding shares. The majority of Ginkgo Bioworks Holdings outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Ginkgo Bioworks to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Ginkgo Bioworks Holdings. Please pay attention to any change in the institutional holdings of Ginkgo Bioworks Holdings as this could imply that something significant has changed or is about to change at the company. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.
Check Ginkgo Ownership Details

Ginkgo Stock Price Odds Analysis

What are Ginkgo Bioworks' target price odds to finish over the current price? Depending on a normal probability distribution, the odds of Ginkgo Bioworks jumping above the current price in 90 days from now is under 95%. The Ginkgo Bioworks Holdings probability density function shows the probability of Ginkgo Bioworks stock to fall within a particular range of prices over 90 days. Considering the 90-day investment horizon the stock has a beta coefficient of 5.1266 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Ginkgo Bioworks will likely underperform. Additionally, the company has a negative alpha, implying that the risk taken by holding this instrument is not justified. Ginkgo Bioworks Holdings is significantly underperforming NYSE Composite.
  Odds Below 1.09HorizonTargetOdds Above 1.09
5.69%90 days
 1.09 
94.28%
Based on a normal probability distribution, the odds of Ginkgo Bioworks to move above the current price in 90 days from now is under 95 (This Ginkgo Bioworks Holdings probability density function shows the probability of Ginkgo Stock to fall within a particular range of prices over 90 days) .

Ginkgo Stock Institutional Holders

Institutional Holdings refers to the ownership stake in Ginkgo Bioworks that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Ginkgo Bioworks' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Ginkgo Bioworks' value.
InstituionRecorded OnShares
Geode Capital Management, Llc2023-09-30
20 M
Norges Bank2023-12-31
14.8 M
Millennium Management Llc2023-09-30
9.3 M
Exor Investments (uk) Llp2023-12-31
8.5 M
Charles Schwab Investment Management Inc2023-09-30
7.4 M
Welch & Forbes Llc2023-12-31
M
Northern Trust Corp2023-09-30
5.9 M
Citadel Advisors Llc2023-09-30
5.2 M
Nordea Investment Mgmt Bank Demark A/s2023-12-31
4.4 M
Baillie Gifford & Co Limited.2023-12-31
236.3 M
Ark Investment Management Llc2023-09-30
182.2 M
View Ginkgo Bioworks Diagnostics

Ginkgo Bioworks Historical Income Statement

Ginkgo Bioworks Holdings Income Statement is one of the three primary financial statements used for reporting Ginkgo's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Ginkgo Bioworks Holdings revenue and expense. Ginkgo Bioworks Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At present, Ginkgo Bioworks' Net Interest Income is projected to increase significantly based on the last few years of reporting. The current year's Interest Income is expected to grow to about 60.1 M, whereas Tax Provision is projected to grow to (13.9 M). View More Fundamentals

Ginkgo Stock Against Markets

Picking the right benchmark for Ginkgo Bioworks stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Ginkgo Bioworks stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Ginkgo Bioworks is critical whether you are bullish or bearish towards Ginkgo Bioworks Holdings at a given time. Please also check how Ginkgo Bioworks' historical prices are related to one of the top price index indicators.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Ginkgo Bioworks without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run AI Portfolio Architect Now

   

AI Portfolio Architect

Use AI to generate optimal portfolios and find profitable investment opportunities
All  Next Launch Module

Ginkgo Bioworks Corporate Directors

Ginkgo Bioworks corporate directors refer to members of a Ginkgo Bioworks board of directors. The board of directors generally takes responsibility for the Ginkgo Bioworks' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Ginkgo Bioworks' board members must vote for the resolution. The Ginkgo Bioworks board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.

How to buy Ginkgo Stock?

Before investing in Ginkgo Bioworks, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Ginkgo Bioworks. To buy Ginkgo Bioworks stock, you can follow these steps:
  • Choose a brokerage firm: You need to select a brokerage firm to buy shares of Ginkgo Bioworks. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
  • Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
  • Fund your account: You will need to deposit funds into your brokerage account to purchase Ginkgo Bioworks stock. You can do this by transferring funds from your bank account or other investment accounts.
  • Place your order: Once you have located Ginkgo Bioworks Holdings stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
  • Monitor your investment: After you have purchased Ginkgo Bioworks Holdings stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Ginkgo Bioworks Holdings, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Ginkgo Stock please use our How to Invest in Ginkgo Bioworks guide.

Already Invested in Ginkgo Bioworks Holdings?

The danger of trading Ginkgo Bioworks Holdings is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Ginkgo Bioworks is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Ginkgo Bioworks. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Ginkgo Bioworks Holdings is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Ginkgo Bioworks Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Ginkgo Bioworks' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Ginkgo Bioworks Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Ginkgo Bioworks Holdings Stock:
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Ginkgo Bioworks Holdings. Also, note that the market value of any Company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.
You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.

Complementary Tools for Ginkgo Stock analysis

When running Ginkgo Bioworks' price analysis, check to measure Ginkgo Bioworks' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ginkgo Bioworks is operating at the current time. Most of Ginkgo Bioworks' value examination focuses on studying past and present price action to predict the probability of Ginkgo Bioworks' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ginkgo Bioworks' price. Additionally, you may evaluate how the addition of Ginkgo Bioworks to your portfolios can decrease your overall portfolio volatility.
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Is Ginkgo Bioworks' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ginkgo Bioworks. If investors know Ginkgo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ginkgo Bioworks listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.46)
Revenue Per Share
0.129
Quarterly Revenue Growth
(0.65)
Return On Assets
(0.22)
Return On Equity
(0.63)
The market value of Ginkgo Bioworks Holdings is measured differently than its book value, which is the value of Ginkgo that is recorded on the company's balance sheet. Investors also form their own opinion of Ginkgo Bioworks' value that differs from its market value or its book value, called intrinsic value, which is Ginkgo Bioworks' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ginkgo Bioworks' market value can be influenced by many factors that don't directly affect Ginkgo Bioworks' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ginkgo Bioworks' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ginkgo Bioworks is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ginkgo Bioworks' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.